Bell KA, Smith Sehdev AE, Kurman RJ (2001) Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol 25:419–432

Article  CAS  PubMed  Google Scholar 

Ahn G, Folkins AK, McKenney JK et al (2016) Low-grade serous carcinoma of the ovary: clinicopathologic analysis of 52 invasive cases and identification of a possible noninvasive intermediate lesion. Am J Surg Pathol 40:1165–1176

Article  PubMed  Google Scholar 

Ayhan A, Guvendag Guven ES, Guven S et al (2005) Recurrence and prognostic factors in borderline ovarian tumors. Gynecol Oncol 98:439–445

Article  PubMed  Google Scholar 

Park JY, Kim DY, Kim JH et al (2009) Surgical management of borderline ovarian tumors: the role of fertility-sparing surgery. Gynecol Oncol 113:75–82

Article  PubMed  Google Scholar 

Hannibal CG, Vang R, Junge J et al (2014) A nationwide study of serous “borderline” ovarian tumors in Denmark 1978–2002: centralized pathology review and overall survival compared with the general population. Gynecol Oncol 134:267–273

Article  PubMed  PubMed Central  Google Scholar 

Longacre TA, McKenney JK, Tazelaar HD et al (2005) Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 29:707–723

Article  PubMed  Google Scholar 

Vang R, Hannibal CG, Junge J et al (2017) Long-term behavior of serous borderline tumors subdivided into atypical proliferative tumors and noninvasive low-grade carcinomas: a population-based clinicopathologic study of 942 cases. Am J Surg Pathol 41:725–737

Article  PubMed  PubMed Central  Google Scholar 

McKenney JK, Balzer BL, Longacre TA (2006) Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification. Am J Surg Pathol 30:614–624

Article  PubMed  Google Scholar 

Seidman JD, Kurman RJ (2000) Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 31:539–557

Article  CAS  PubMed  Google Scholar 

Prat J, De Nictolis M (2002) Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol 26:1111–1128

Article  PubMed  Google Scholar 

Bell DA, Longacre TA, Prat J et al (2004) Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol 35:934–948

Article  PubMed  Google Scholar 

Hannibal CG, Vang R, Junge J et al (2017) A nationwide study of ovarian serous borderline tumors in Denmark 1978–2002. Risk of recurrence, and development of ovarian serous carcinoma. Gynecol Oncol 144:174–180

Article  PubMed  Google Scholar 

Chui MH, Xing D, Zeppernick F et al (2019) Clinicopathologic and molecular features of paired cases of metachronous ovarian serous borderline tumor and subsequent serous carcinoma. Am J Surg Pathol 43:1462–1472

Article  PubMed  PubMed Central  Google Scholar 

Singer G, Oldt R 3rd, Cohen Y et al (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484–486

Article  CAS  PubMed  Google Scholar 

Ho CL, Kurman RJ, Dehari R et al (2004) Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 64:6915–6918

Article  CAS  PubMed  Google Scholar 

Jones S, Wang TL, Kurman RJ et al (2012) Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 226:413–420

Article  CAS  PubMed  Google Scholar 

Hunter SM, Anglesio MS, Ryland GL et al (2015) Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget 6:37663–37677

Article  PubMed  PubMed Central  Google Scholar 

Krzystyniak J, Ceppi L, Dizon DS et al (2016) Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer. Ann Oncol 27(Suppl 1):i4–i10

Article  PubMed  PubMed Central  Google Scholar 

Anglesio MS, Arnold JM, George J et al (2008) Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 6:1678–1690

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xing D, Suryo Rahmanto Y, Zeppernick F et al (2017) Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma. Hum Pathol 68:87–91

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zuo T, Wong S, Buza N et al (2018) KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome. Mod Pathol 31:350–357

Article  CAS  PubMed  Google Scholar 

Chui MH, Kjaer SK, Frederiksen K et al (2019) BRAF(V600E) -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma. Oncotarget 10:6870–6878

Article  PubMed  PubMed Central  Google Scholar 

Tsang YT, Deavers MT, Sun CC et al (2013) KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol 231:449–456

Article  CAS  PubMed  PubMed Central  Google Scholar 

WHO (2020) Classification of Tumours 5th Edition - Female Genital Tumours. (IARC Press, Lyon, France

Zhong H, Liu Y, Talmor M et al (2013) Deparaffinization and lysis by hydrothermal pressure (pressure cooking) coupled with chaotropic salt column purification: a rapid and efficient method of DNA extraction from formalin-fixed paraffin-embedded tissue. Diagn Mol Pathol 22:52–58

Article  CAS  PubMed  Google Scholar 

Dillon DA, Johnson CC, Topazian MD et al (2000) The utility of Ki-ras mutation analysis in the cytologic diagnosis of pancreatobiliary neoplasma. Cancer J 6:294–301

CAS  PubMed  Google Scholar 

Metzker ML (2005) Emerging technologies in DNA sequencing. Genome Res 15:1767–1776

Article  CAS  PubMed  Google Scholar 

Mayr D, Hirschmann A, Löhrs U et al (2006) KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 103:883–887

Article  CAS  PubMed  Google Scholar 

Ardighieri L, Zeppernick F, Hannibal CG et al (2014) Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants. J Pathol 232:16–22

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gershenson DM, Sun CC, Westin SN et al (2022) The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol 165:560–567

Article  CAS  PubMed  Google Scholar 

Malpica A, Wong KK (2016) The molecular pathology of ovarian serous borderline tumors. Ann Oncol 27(Suppl 1):i16–i19

Article  PubMed  PubMed Central  Google Scholar 

Silva EG, Tornos C, Zhuang Z et al (1998) Tumor recurrence in stage I ovarian serous neoplasms of low malignant potential. Int J Gynecol Pathol 17:1–6

Article  CAS  PubMed  Google Scholar 

Grisham RN, Iyer G, Garg K et al (2013) BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 119:548–554

Article  CAS  PubMed  Google Scholar 

Wong KK, Tsang YT, Deavers MT et al (2010) BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol 177:1611–1617

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zeppernick F, Ardighieri L, Hannibal CG et al (2014) BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors. Am J Surg Pathol 38:1603–1611

Article  PubMed  PubMed Central  Google Scholar